Additionally, double gene molecular subtype analysis with SUMO1, SUMO2, and XPO1 genes revealed survival outcome differences across molecular subtypes, further emphasizing NOP58’s critical role in prostate cancer biology and patient prognosis (Figures A1–C5). This evidence concerns the gene SUMO1 and prostate carcinoma.